<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Combinatorial Chemistry &amp; High Throughput Screening</journal-id><journal-title-group><journal-title xml:lang="en">Combinatorial Chemistry &amp; High Throughput Screening</journal-title><trans-title-group xml:lang="ru"><trans-title>Combinatorial Chemistry &amp; High Throughput Screening</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1386-2073</issn><issn publication-format="electronic">1875-5402</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">645271</article-id><article-id pub-id-type="doi">10.2174/0113862073283304231118155730</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Chemical Probes Review: Choosing the Right Path Towards Pharmacological Targets in Drug Discovery, Challenges and Future Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahuja</surname><given-names>Ashima</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sonia</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Murti</surname><given-names>Yogesh</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Institute of Pharmaceutical Research, GLA University</institution></aff><aff id="aff2"><institution>Institute of Pharmaceutical Research,, GLA University</institution></aff><pub-date date-type="pub" iso-8601-date="2024-09-01" publication-format="electronic"><day>01</day><month>09</month><year>2024</year></pub-date><volume>27</volume><issue>17</issue><issue-title xml:lang="ru"/><fpage>2544</fpage><lpage>2564</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjpbr.com/1386-2073/article/view/645271">https://rjpbr.com/1386-2073/article/view/645271</self-uri><abstract xml:lang="en"><p id="idm46041443641008">:Chemical probes are essential for academic research and target validation for disease identification. They facilitate drug discovery, target function investigation, and translation studies. A chemical probe provides starting material that can accelerate therapeutic values and safety measures for identifying any biological target in drug discovery. Essential read outs depend on their versatility in biochemical testing, proving the hypothesis, selectivity, specificity, affinity towards the target site, and valuable in new therapeutic approaches. Disease management will depend upon chemical probes as a primitive tool to ascertain the physicochemical stability for in vivo and in vitro studies useful for clinical trials and industrial application in the future. For cancer research, bacterial infection, and neurodegenerative disorders, chemical probes are integrated circuits which are on pipeline for the drug discovery process Furthermore, pharmacological modulators incorporate activators, crosslinkers, degraders, and inhibitors. Reports accessed depend on their structural, mechanical, biochemical, and pharmacological characterization in drug discovery research. The perspective for designing any chemical probes concludes with the utilization of drug discovery and identification of the potential target. It focuses mainly on evidence-based studies and produces promising results in successfully delivering novel therapeutics to treat cancers and other disorders at the target site. Moreover, natural product pharmacophores like rapamycin, cephalosporin, and β-lactamase are utilized for drug discovery. Chemical probes revolutionize computational-based study design depending on identifying novel targets within the database framework. Chemical probes are the clinical answers for drug development and goforward tools in solving other riddles for scientists and researchers working in this industries.</p></abstract><kwd-group xml:lang="en"><kwd>Chemical probes</kwd><kwd>natural product</kwd><kwd>drug discovery</kwd><kwd>cancer</kwd><kwd>novel therapeutics</kwd><kwd>disease management</kwd><kwd>target validation</kwd><kwd>modulator.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Stark, H. The chemical probe  scopes, limitations and challenges. Expert Opin. Drug Discov., 2020, 15(12), 1365-1367. doi: 10.1080/17460441.2020.1781086 PMID: 32551991</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Litterman, N.K.; Lipinski, C.A.; Bunin, B.A.; Ekins, S. Computational prediction and validation of an experts evaluation of chemical probes. J. Chem. Inf. Model., 2014, 54(10), 2996-3004. doi: 10.1021/ci500445u PMID: 25244007</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Advancing Biomedical Research with Quality Chemical Probes. Advancing Biomedical Research with Quality Chemical Probes. Available from: https://www.promega.in/resources/pubhub/features/advancing-biomedical-research-with-quality-chemical-probes/</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bunnage, M.E.; Chekler, E.L.P.; Jones, L.H. Target validation using chemical probes. Nat. Chem. Biol., 2013, 9(4), 195-199. doi: 10.1038/nchembio.1197 PMID: 23508172</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wagner, BK CHAPTER 1: Introduction to chemical probes, in the discovery and utility of chemical probes in target discovery 2020, 1-13.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cohen, P. Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. Biochem. J., 2010, 425(1), 53-54. doi: 10.1042/BJ20091428 PMID: 20001962</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351(1), 95-105. doi: 10.1042/bj3510095 PMID: 10998351</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Edwards, A.M.; Bountra, C.; Kerr, D.J.; Willson, T.M. Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol., 2009, 5(7), 436-440. doi: 10.1038/nchembio0709-436 PMID: 19536100</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Boyce, S.; Hill, R.G. Proceedings of the 9th world congress on pain, 2000, pp. 313-324.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Euler, V. U.S. in neurotransmitters in action; Bousfield, D., Ed.; Elsevier Biomedical Press: Amsterdam, 1985, pp. 143-150.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Weigelt, J.; McBroom-Cerajewski, L.D.B.; Schapira, M.; Zhao, Y.; Arrowmsmith, C.H. Structural genomics and drug discovery: All in the family. Curr. Opin. Chem. Biol., 2008, 12(1), 32-39. doi: 10.1016/j.cbpa.2008.01.045 PMID: 18282486</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Workman, P.; Collins, I. Probing the probes: Fitness factors for small molecule tools. Chem. Biol., 2010, 17(6), 561-577. doi: 10.1016/j.chembiol.2010.05.013 PMID: 20609406</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Albert, A. Objective, quantitative, data-driven assessment of chemical probes. Cell Chem. Biol., 2018, 25, 194-205. doi: 10.1016/j.chembiol.2017.11.004 PMID: 29249694</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dowling, J.E.; Chuaqui, C.; Pontz, T.W.; Lyne, P.D.; Larsen, N.A.; Block, M.H.; Chen, H.; Su, N.; Wu, A.; Russell, D.; Pollard, H.; Lee, J.W.; Peng, B.; Thakur, K.; Ye, Q.; Zhang, T.; Brassil, P.; Racicot, V.; Bao, L.; Denz, C.R.; Cooke, E. Potent and selective inhibitors of CK2 kinase identified through structure-guided hybridization. ACS Med. Chem. Lett., 2012, 3(4), 278-283. doi: 10.1021/ml200257n PMID: 24900464</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zhou, Y.; Zhang, N.; Tang, S.; Qi, X.; Zhao, L.; Zhong, R.; Peng, Y. Exploring the pivotal role of the CK2 hinge region sub-pocket in binding with tricyclic quinolone analogues by computational analysis. Molecules, 2017, 22(5), 840. doi: 10.3390/molecules22050840 PMID: 28534839</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; David, H. Drewry; Edwards, Aled.; Fabbro, Doriano.; Gillespie, Paul.; Gray, Nathanael S.; Kuster, Bernhard.; Lackey, Karen E; Mazzafera, Paulo.; Tomkinson, Nicholas C O.; Willson, Timothy M.; Gray, Paul; J Zuercher, William. A public-private partnership to unlock the untargeted kinome. Nat. Chem. Biol., 2013, 9, 1-7.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Patricelli, M.P.; Nomanbhoy, T.K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J.D.; Gray, N.S.; Kozarich, J.W. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol., 2011, 18(6), 699-710. doi: 10.1016/j.chembiol.2011.04.011 PMID: 21700206</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Deepa, P.; Thirumeignanam, D. Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF3, CH3, NH2, OH, H) of casein kinase 2 (CK2). J. Biomol. Struct. Dyn., 2022, 40(11), 5036-5052. doi: 10.1080/07391102.2020.1866075 PMID: 33375908</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Atkinson, E.L.; Iegre, J.; Brear, P.D.; Zhabina, E.A.; Hyvönen, M.; Spring, D.R. Downfalls of chemical probes acting at the kinase ATP-Site: CK2 as a case study. Molecules, 2021, 26(7), 1977. doi: 10.3390/molecules26071977 PMID: 33807474</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pardhi, T.; Vasu, K. Identification of dual kinase inhibitors of CK2 and GSK3β: Combined qualitative and quantitative pharmacophore modeling approach. J. Biomol. Struct. Dyn., 2018, 36(1), 177-194. doi: 10.1080/07391102.2016.1270856 PMID: 27960601</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Stone, Samantha; J, David.;, Newman; Colletti, Steven L.; S. Tan, Derek Cheminformatic analysis of natural product-based drugs and chemical probes. Natural products as chemical probes. Nat. Prod. Rep., 2022, 39, 20-32.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Carlson, E.E. Natural products as chemical probes. ACS Chem. Biol., 2010, 5(7), 639-653. doi: 10.1021/cb100105c PMID: 20509672</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sehgal, S.N.; Baker, H.; Vézina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo), 1975, 28(10), 727-732. doi: 10.7164/antibiotics.28.727 PMID: 1102509</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Abraham, R.T. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol., 1998, 10(3), 330-336. doi: 10.1016/S0952-7915(98)80172-6 PMID: 9638370</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Fingar, D.C.; Blenis, J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004, 23(18), 3151-3171. doi: 10.1038/sj.onc.1207542 PMID: 15094765</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Heitman, J.; Movva, N.R.; Hall, M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 1991, 253(5022), 905-909. doi: 10.1126/science.1715094 PMID: 1715094</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Crespo, J.L.; Hall, M.N. Elucidating TOR signaling and rapamycin action: Lessons from Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev., 2002, 66(4), 579-591. doi: 10.1128/MMBR.66.4.579-591.2002 PMID: 12456783</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Vézina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo), 1975, 28(10), 721-726. doi: 10.7164/antibiotics.28.721 PMID: 1102508</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Harding, M.W.; Galat, A.; Uehling, D.E.; Schreiber, S.L. A receptor for the immuno-suppressant FK506 is a cistrans peptidyl-prolyl isomerase. Nature, 1989, 341(6244), 758-760. doi: 10.1038/341758a0 PMID: 2477715</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Bierer, B.E.; Mattila, P.S.; Standaert, R.F.; Herzenberg, L.A.; Burakoff, S.J.; Crabtree, G.; Schreiber, S.L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA, 1990, 87(23), 9231-9235. doi: 10.1073/pnas.87.23.9231 PMID: 2123553</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Dancey, J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol., 2010, 7(4), 209-219. doi: 10.1038/nrclinonc.2010.21 PMID: 20234352</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Roberts, B.E.; Duennwald, M.L.; Wang, H.; Chung, C.; Lopreiato, N.P.; Sweeny, E.A.; Knight, M.N.; Shorter, J. A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat. Chem. Biol., 2009, 5(12), 936-946. doi: 10.1038/nchembio.246 PMID: 19915541</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Patury, S.; Miyata, Y.; Gestwicki, J. Pharmacological targeting of the Hsp70 chaperone. Curr. Top. Med. Chem., 2009, 9(15), 1337-1351. doi: 10.2174/156802609789895674 PMID: 19860737</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Evans, CG; Chang, L; Gestwicki, JE Heat shock protein 70 (Hsp70) as an emerging drug target. J Med Chem, 2010. Epub Mar 24</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Butt, M.S.; Sultan, M.T. Green tea: Natures defense against malignancies. Crit. Rev. Food Sci. Nutr., 2009, 49(5), 463-473. doi: 10.1080/10408390802145310 PMID: 19399671</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Jinwal, U.K.; Miyata, Y.; Koren, J., III; Jones, J.R.; Trotter, J.H.; Chang, L.; OLeary, J.; Morgan, D.; Lee, D.C.; Shults, C.L.; Rousaki, A.; Weeber, E.J.; Zuiderweg, E.R.P.; Gestwicki, J.E.; Dickey, C.A. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci., 2009, 29(39), 12079-12088. doi: 10.1523/JNEUROSCI.3345-09.2009 PMID: 19793966</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimers disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39(3), 409-421. doi: 10.1016/S0896-6273(03)00434-3 PMID: 12895417</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Castellanos-Ortega, M.R.; Cruz-Aguado, R.; Martínez-Martí, L. Nerve growth factor: Possibilities and limitations of its clinical application. Rev. Neurol., 1999, 29(5), 439-447. PMID: 10584248</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Skovronsky, D.M.; Lee, V.M.Y.; Trojanowski, J.Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol., 2006, 1(1), 151-170. doi: 10.1146/annurev.pathol.1.110304.100113 PMID: 18039111</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Shigemori, H.; Wakuri, S.; Yazawa, K.; Nakamura, T.; Sasaki, T.; Kobayashi, J. Fellutamides A and B, cytotoxic peptides from a marine fish-possessing fungus Penicillium fellutanum. Tetrahedron, 1991, 47(40), 8529-8534. doi: 10.1016/S0040-4020(01)82396-6</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Hines, J.; Groll, M.; Fahnestock, M.; Crews, C.M. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem. Biol., 2008, 15(5), 501-512. doi: 10.1016/j.chembiol.2008.03.020 PMID: 18482702</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Yamaguchi, K.; Tsuji, T.; Wakuri, S.; Yazawa, K.; Kondo, K.; Shigemori, H.; Kobayashi, J. Stimulation of nerve growth factor synthesis and secretion by fellutamide A in vitro. Biosci. Biotechnol. Biochem., 1993, 57(2), 195-199. doi: 10.1271/bbb.57.195 PMID: 7763492</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Brody, L.C.; Mitchell, G.A.; Obie, C.; Michaud, J.; Steel, G.; Fontaine, G.; Robert, M.F.; Sipila, I.; Kaiser-Kupfer, M.; Valle, D. Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences. J. Biol. Chem., 1992, 267(5), 3302-3307. doi: 10.1016/S0021-9258(19)50731-1 PMID: 1737786</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Wood, K.; Cornwell, W.D.; Jackson, J.R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol., 2001, 1(4), 370-377. doi: 10.1016/S1471-4892(01)00064-9 PMID: 11710735</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Cruz-Monserrate, Z.; Vervoort, H.C.; Bai, R.; Newman, D.J.; Howell, S.B.; Los, G.; Mullaney, J.T.; Williams, M.D.; Pettit, G.R.; Fenical, W.; Hamel, E. Diazonamide A and a synthetic structural analog: Disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol. Pharmacol., 2003, 63(6), 1273-1280. doi: 10.1124/mol.63.6.1273 PMID: 12761336</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Williams, N.S.; Burgett, A.W.G.; Atkins, A.S.; Wang, X.; Harran, P.G.; McKnight, S.L. Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity. Proc. Natl. Acad. Sci. USA, 2007, 104(7), 2074-2079. doi: 10.1073/pnas.0611340104 PMID: 17287337</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Wang, G.; Shang, L.; Burgett, A.W.G.; Harran, P.G.; Wang, X. Diazonamide toxins reveal an unexpected function for ornithine δ-amino transferase in mitotic cell division. Proc. Natl. Acad. Sci. USA, 2007, 104(7), 2068-2073. doi: 10.1073/pnas.0610832104 PMID: 17287350</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Wang, T.; Lawler, A.M.; Steel, G.; Sipila, I.; Milam, A.H.; Valle, D. Mice lacking ornithineδaminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Nat. Genet., 1995, 11(2), 185-190. doi: 10.1038/ng1095-185 PMID: 7550347</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Lindquist, N.; Fenical, W.; Van Duyne, G.D.; Clardy, J. Isolation and structure determination of diazonamides A and B, unusual cytotoxic metabolites from the marine ascidian Diazona chinensis. J. Am. Chem. Soc., 1991, 113(6), 2303-2304. doi: 10.1021/ja00006a060</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Seiler, N. Ornithine aminotransferase, a potential target for the treatment of hyperammonemias. Curr. Drug Targets, 2000, 1(2), 119-154. doi: 10.2174/1389450003349254 PMID: 11465067</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Frye, S.V. The art of the chemical probe. Nat. Chem. Biol., 2010, 6(3), 159-161. doi: 10.1038/nchembio.296 PMID: 20154659</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Kolbe, K.; Veleti, S.K.; Johnson, E.E.; Cho, Y.W.; Oh, S.; Barry, C.E. III; Cho, Young-Woo; S, Oh; CE, Barry Role of chemical biology in tuberculosis drug discovery and diagnosis. ACS Infect. Dis., 2018, 4(4), 458-466. doi: 10.1021/acsinfecdis.7b00242 PMID: 29364647</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Lee, J.; Schapira, M. The promise and peril of chemical probe negative controls. ACS Chem. Biol., 2021, 16(4), 579-585. doi: 10.1021/acschembio.1c00036 PMID: 33745272</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Castaldi, M.P.; Hendricks, J.A.; Zhang, A.X. Design, synthesis, and strategic use of small chemical probes toward identification of novel targets for drug development. Curr. Opin. Chem. Biol., 2020, 56, 91-97. doi: 10.1016/j.cbpa.2020.03.003 PMID: 32375076</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Zhu, H.; Hamachi, I. Fluorescence imaging of drug target proteins using chemical probes. J. Pharm. Anal., 2020, 10(5), 426-433. doi: 10.1016/j.jpha.2020.05.013 PMID: 33133726</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Ortega, C.; Anderson, L.N.; Frando, A.; Sadler, N.C.; Brown, R.W.; Smith, R.D.; Wright, A.T.; Grundner, C. Systematic survey of serine hydrolase activity in mycobacterium tuberculosis defines changes associated with persistence. Cell Chem. Biol., 2016, 23(2), 290-298. doi: 10.1016/j.chembiol.2016.01.003 PMID: 26853625</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Tallman, K.R.; Levine, S.R.; Beatty, K.E. Profiling esterases in mycobacterium tuberculosis using far-red fluorogenic substrates. ACS Chem. Biol., 2016, 11(7), 1810-1815. doi: 10.1021/acschembio.6b00233 PMID: 27177211</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Tallman, K.R.; Levine, S.R.; Beatty, K.E. Small-molecule probes reveal esterases with persistent activity in dormant and reactivating mycobacterium tuberculosis. ACS Infect. Dis., 2016, 2(12), 936-944. doi: 10.1021/acsinfecdis.6b00135 PMID: 27690385</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Lentz, C.S.; Ordonez, A.A.; Kasperkiewicz, P.; La Greca, F.; ODonoghue, A.J.; Schulze, C.J.; Powers, J.C.; Craik, C.S.; Drag, M.; Jain, S.K.; Bogyo, M. Design of selective substrates and activity-based probes for hydrolase important for pathogenesis 1 (HIP1) from Mycobacterium tuberculosis. ACS Infect. Dis., 2016, 2(11), 807-815. doi: 10.1021/acsinfecdis.6b00092 PMID: 27739665</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Ansong, C.; Ortega, C.; Payne, S.H.; Haft, D.H.; Chauvignè-Hines, L.M.; Lewis, M.P.; Ollodart, A.R.; Purvine, S.O.; Shukla, A.K.; Fortuin, S.; Smith, R.D.; Adkins, J.N.; Grundner, C.; Wright, A.T. Identification of widespread adenosine nucleotide binding in Mycobacterium tuberculosis. Chem. Biol., 2013, 20(1), 123-133. doi: 10.1016/j.chembiol.2012.11.008 PMID: 23352146</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Wolfe, L.M.; Veeraraghavan, U.; Idicula-Thomas, S.; Schürer, S.; Wennerberg, K.; Reynolds, R.; Besra, G.S.; Dobos, K.M. A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis. Mol. Cell. Proteomics, 2013, 12(6), 1644-1660. doi: 10.1074/mcp.M112.025635 PMID: 23462205</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Benjamin, P. Duckworth; Wilson, Daniel J.; M. Nelson, Kathryn; Boshoff, Helena I.; Barry, Clifton E., III; Aldrich, Courtney C. Development of a selective activity-based probe for adenylating enzymes: Profiling mbta involved in siderophore biosynthesis from mycobacterium tuberculosis. ACS Chem. Biol., 2012, 7(10), 1653-1658. doi: 10.1021/cb300112x PMID: 22796950</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Carlson, E.E.; May, J.F.; Kiessling, L.L. Chemical probes of UDP-galactopyranose mutase. Chem. Biol., 2006, 13(8), 825-837. doi: 10.1016/j.chembiol.2006.06.007 PMID: 16931332</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Kastrinsky, D.B.; Barry, C.E., III Synthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases. Tetrahedron Lett., 2010, 51(1), 197-200. doi: 10.1016/j.tetlet.2009.10.124 PMID: 20161438</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Kong, Y.; Yao, H.; Ren, H.; Subbian, S.; Cirillo, S.L.G.; Sacchettini, J.C.; Rao, J.; Cirillo, J.D. Imaging tuberculosis with endogenous β-lactamase reporter enzyme fluorescence in live mice. Proc. Natl. Acad. Sci. USA, 2010, 107(27), 12239-12244. doi: 10.1073/pnas.1000643107 PMID: 20566877</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Xie, H.; Mire, J.; Kong, Y.; Chang, M.; Hassounah, H.A.; Thornton, C.N.; Sacchettini, J.C.; Cirillo, J.D.; Rao, J. Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe. Nat. Chem., 2012, 4(10), 802-809. doi: 10.1038/nchem.1435 PMID: 23000993</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Cheng, Y.; Xie, H.; Sule, P.; Hassounah, H.; Graviss, E.A.; Kong, Y.; Cirillo, J.D.; Rao, J. Fluorogenic probes with substitutions at the 2 and 7 positions of cephalosporin are highly BlaC-specific for rapid Mycobacterium tuberculosis detection. Angew. Chem. Int. Ed., 2014, 53(35), 9360-9364. doi: 10.1002/anie.201405243 PMID: 24989449</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Carlson, E.E.; Cravatt, B.F. Chemoselective probes for metabolite enrichment and profiling. Nat. Methods, 2007, 4(5), 429-435. doi: 10.1038/nmeth1038 PMID: 17417646</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Blum, G.; von Degenfeld, G.; Merchant, M.J.; Blau, H.M.; Bogyo, M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol., 2007, 3(10), 668-677. doi: 10.1038/nchembio.2007.26 PMID: 17828252</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Blum, G.; Mullins, S.R.; Keren, K.; Fonovič, M.; Jedeszko, C.; Rice, M.J.; Sloane, B.F.; Bogyo, M. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol., 2005, 1(4), 203-209. doi: 10.1038/nchembio728 PMID: 16408036</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Alexandra, J. Lukasiewicza; Contrerasa, Lydia M. Antisense probing of dynamic RNA structures. Methods, 2020, 1-8.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Russell, R.; Herschlag, D. Probing the folding landscape of the Tetrahymena ribozyme: Commitment to form the native conformation is late in the folding pathway. J. Mol. Biol., 2001, 308(5), 839-851. doi: 10.1006/jmbi.2001.4751 PMID: 11352576</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Hefti, A.F. Periodontal probing. Crit. Rev. Oral Biol. Med., 1997, 8(3), 336-356. doi: 10.1177/10454411970080030601 PMID: 9260047</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Ding, Y.; Li, Z.; Xu, C.; Qin, W.; Wu, Q.; Wang, X.; Cheng, X.; Li, L.; Huang, W. Fluorogenic probes/inhibitors of β‐lactamase and their applications in drug‐resistant bacteria. Angew. Chem. Int. Ed., 2021, 60(1), 24-40. doi: 10.1002/anie.202006635 PMID: 32592283</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>New noninvasive chemical probe detects common species of staph bacteria in the body. Available from: https://www.news-medical.net/news/20140203/New-noninvasive-chemical-probe-detects-common-species-of-staph-bacteria-in-the-body.aspx</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Yoon, S.A.; Park, S.Y.; Cha, Y.; Gopala, L.; Lee, M.H. Strategies of detecting bacteria using fluorescence-based dyes. Front Chem., 2021, 9, 743923. doi: 10.3389/fchem.2021.743923</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Available from: https://www.pnnl.gov/science/highlights/highlight.asp?id=1266</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Zhang, C.; Stockwell, S.R.; Elbanna, M.; Ketteler, R.; Freeman, J.; Al-Lazikani, B.; Eccles, S.; De Haven Brandon, A.; Raynaud, F.; Hayes, A.; Clarke, P.A.; Workman, P.; Mittnacht, S. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38(30), 5905-5920. doi: 10.1038/s41388-019-0850-2 PMID: 31296956</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Antolin, A.A.; Workman, P.; Al-Lazikani, B. Public resources for chemical probes: the journey so far and the road ahead. Future Med. Chem., 2021, 13(8), 731-747.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Paiva, S.L.; Crews, C.M. Targeted protein degradation: Elements of PROTAC design. Curr. Opin. Chem. Biol., 2019, 50, 111-119. doi: 10.1016/j.cbpa.2019.02.022 PMID: 31004963</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Workman, P.; Antolin, A.A.; Al-Lazikani, B. Transforming cancer drug discovery with Big Data and AI. Expert Opin. Drug Discov., 2019, 14(11), 1089-1095. doi: 10.1080/17460441.2019.1637414 PMID: 31284790</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Mullard, A. A probe for every protein. Nat. Rev. Drug Discov., 2019, 18(10), 733-736. doi: 10.1038/d41573-019-00159-9 PMID: 31570852</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Jones, L.H. Cell permeable affinity- and activity-based probes. Future Med. Chem., 2015, 7(16), 2131-2141. doi: 10.4155/fmc.15.100 PMID: 26511518</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Available from: https://patents.google.com/patent/WO2010114599A1</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Available from: https://patents.google.com/patent/US8962853B2/en</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Available from: https://patents.google.com/patent/US8697357</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Available from: https://pubchem.ncbi.nlm.nih.gov/patent/US-10704087-B2</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Available from: https://patents.google.com/patent/US7375198</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Lai, H.M.; Ng, W.L.; Gentleman, S.M.; Wu, W. Chemical probes for visualizing intact animal and human brain tissue. Cell Chem. Biol., 2017, 24(6), 659-672. doi: 10.1016/j.chembiol.2017.05.015 PMID: 28644957</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Chang, W.M.; Dakanali, M.; Capule, C.C.; Sigurdson, C.J.; Yang, J.; Theodorakis, E.A. ANCA: A family of fluorescent probes that bind and stain amyloid plaques in human tissue. ACS Chem. Neurosci., 2011, 2(5), 249-255. doi: 10.1021/cn200018v PMID: 21743829</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>McMurray, L.; Macdonald, J.A.; Ramakrishnan, N.K.; Zhao, Y.; Williamson, D.W.; Tietz, O.; Zhou, X.; Kealey, S.; Fagan, S.G.; Smolek, T.; Cubinkova, V.; ilka, N.; Spillantini, M.G.; Tolkovsky, A.M.; Goedert, M.; Aigbirhio, F.I. Synthesis and assessment of novel probes for imaging tau pathology in transgenic mouse and rat models. ACS Chem. Neurosci., 2021, 12(11), 1885-1893. doi: 10.1021/acschemneuro.0c00790 PMID: 33689290</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Watanabe, H. Development of SPECT probes for in vivo imaging of β-amyloid and tau aggregates in the alzheimers disease brain. Pharmacy Magazine, 2017, 137(11), 1361-1365. doi: 10.1248/yakushi.17-00156 PMID: 29093372</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Ono, M.; Watanabe, H.; Kitada, A.; Matsumura, K.; Ihara, M.; Saji, H. Highly selective Tau-SPECT imaging probes for detection of neurofibrillary tangles in alzheimers disease. Sci. Rep., 2016, 6(1), 34197. doi: 10.1038/srep34197 PMID: 27687137</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Cui, M. Past and recent progress of molecular imaging probes for β-amyloid plaques in the brain. Curr. Med. Chem., 2013, 21(1), 82-112. doi: 10.2174/09298673113209990216 PMID: 23992340</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Brelstaff, J.; Ossola, B.; Neher, J.J.; Klingstedt, T.; Nilsson, K.P.R.; Goedert, M.; Spillantini, M.G.; Tolkovsky, A.M. The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Front. Neurosci., 2015, 9, 184. doi: 10.3389/fnins.2015.00184 PMID: 26074756</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Blau, R.; Shelef, O.; Shabat, D.; Satchi-Fainaro, R. Chemiluminescent probes in cancer biology. Nat. Rev. Bioeng., 2023, 1(9), 648-664. doi: 10.1038/s44222-023-00074-0</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Benezra, M.; Penate-Medina, O.; Zanzonico, P.B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S.; Wolchok, J.; Larson, S.M.; Wiesner, U.; Bradbury, M.S. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest., 2011, 121(7), 2768-2780. doi: 10.1172/JCI45600 PMID: 21670497</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>van Dam, G.M.; Themelis, G.; Crane, L.M.A.; Harlaar, N.J.; Pleijhuis, R.G.; Kelder, W.; Sarantopoulos, A.; de Jong, J.S.; Arts, H.J.G.; van der Zee, A.G.J.; Bart, J.; Low, P.S.; Ntziachristos, V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat. Med., 2011, 17(10), 1315-1319. doi: 10.1038/nm.2472 PMID: 21926976</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Lamberts, L.E.; Koch, M.; de Jong, J.S.; Adams, A.L.L.; Glatz, J.; Kranendonk, M.E.G.; Terwisscha van Scheltinga, A.G.T.; Jansen, L.; de Vries, J.; Lub-de Hooge, M.N.; Schröder, C.P.; Jorritsma-Smit, A.; Linssen, M.D.; de Boer, E.; van der Vegt, B.; Nagengast, W.B.; Elias, S.G.; Oliveira, S.; Witkamp, A.J.; Mali, W.P.T.M.; Van der Wall, E.; van Diest, P.J.; de Vries, E.G.E.; Ntziachristos, V.; van Dam, G.M. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: A phase I feasibility study. Clin. Cancer Res., 2017, 23(11), 2730-2741. doi: 10.1158/1078-0432.CCR-16-0437 PMID: 28119364</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Seah, D.; Cheng, Z.; Vendrell, M. Fluorescent probes for imaging in humans: Where are we now? ACS Nano, 2023, 17(20), 19478-19490. doi: 10.1021/acsnano.3c03564 PMID: 37787658</mixed-citation></ref></ref-list></back></article>
